For Immediate Release
Chicago, IL – February 16, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Charles Schwab Corp. (SCHW), E*TRADE Financial Corporation (ETFC), TD Ameritrade Holding Corporation (AMTD), Amylin Pharmaceuticals, Inc. (:AMLN) and Alkermes plc (ALKS).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Schwab Reports Rise in DARTs
On Tuesday, Charles Schwab Corp. (SCHW) released its Monthly Activity Report for January 2012, recording an increase of 8% in Daily Average Revenue Trades (DARTs) from December 2011 to 468,400. However, the company’s DARTs declined 8% year over year. This year-over-year fall in DARTs was mainly attributable to the absence of a seasonal rise in transactions involving Schwab Mutual Fund OneSource product.
Schwab registered a fall in new assets, with net inflow of $7.1 billion in January 2012 as against $10.5 billion in December 2011. However, new assets surged from $6.4 billion recorded in the prior-year month.
Further, Schwab’s total client assets stood at $1.74 trillion as of January-end, rising 4% from $1.68 trillion in the prior month and 9% from $1.59 trillion in the prior-year comparable period. The company opened 74,000 brokerage accounts in January 2012, slipping 1% from 75,000 in December 2011 but in line with January 2011.
At the end of the reported month, Schwab’s active brokerage accounts totaled 8.572 million; flat sequentially but up 7% year over year. Moreover, clients’ banking accounts grew 1% sequentially and 12% year over year to 787,000 for January. Similarly, the number of corporate retirement plan participants was 1,504 million, improving 1% from December 2011 and 3% from January 2011.
Earlier in the week, E*TRADE Financial Corporation (ETFC) also recorded a sequential rise in DARTs. For January 2012, DARTs were 145,390, up 20% sequentially. However, DARTs fell 20% from the year-ago period due to high market volatility, which pushed investors to the sidelines.
Similarly, last week, TD Ameritrade Holding Corporation (AMTD) recorded a sequential rise and year-over-year fall in DARTs for January 2012. The company’s DARTs were 374,000, jumping 18% sequentially, but dipping 17% year over year.
We believe that the optionsXpress deal will likely boost Schwab’s top line to some extent. While a focus on lower-cost capital structure will help sustain better results in the upcoming quarters, the company’s financials will continue to be impacted by lower trading activity and volatile interest rates. We are also concerned about the company’s lower degree of capital intensity relative to its peers.
Schwab currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Also, considering the fundamentals, we maintain a long-term Neutral” recommendation on the stock.
Amylin’s Bydureon Launches in the U.S.
Amylin Pharmaceuticals, Inc. (:AMLN) and Alkermes plc (ALKS) recently announced the availability of their type II diabetes treatment, Bydureon (exenatide once-weekly) in the US.
Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist, gained approval earlier this year as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes. This means that Bydureon can be used as a monotherapy, as well as in combination with commonly prescribed oral diabetes therapies.
Approval was granted with a Risk Evaluation and Mitigation Strategy (:REMS) and post-marketing requirements. The REMS will keep healthcare professionals informed about the risk of acute pancreatitis and the potential risk of thyroid C-cell tumors associated with the use of Bydureon, and ensure that the benefits of Bydureon outweigh these potential risks.
Amylin has been preparing for the US launch of Bydureon. The company has two commercial units -- one focused on exenatide and the other on specialty and orphan diseases.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
More From Zacks.com